Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immuron.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Immuron gives vicious cycle kick in the guts
Health & Biotech
ASX Health Winners March: A rebound? Aussie biotech sector is on the radar of Asian investors
News
Hot Money Monday: ‘Cut losses and let winners run’ – advice from legendary momentum trader Paul Tudor Jones
News
ASX Small Caps and IPO Weekly Wrap: Gold and medicine are the best medicine
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX dragged down by ex-divvy stocks as banks take lead; Gold’s rally relentless
News
ASX Small Caps Lunch Wrap: Which old timey space adventurer is on its last legs this week?
Health & Biotech
ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3
Health & Biotech
ASX Health Stocks: Immuron reports record sales for its diarrhoea drug, Travelan
Health & Biotech
ASX Health Stocks: Immuron chalks up record half for travelers’ diarrhoea medicine, Travelan
News
Closing Bell: Local markets ignore the conflict, follow the money to a fifth day of wins
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
Health & Biotech
ASX Health Stocks: Cann’s cannabis flower sales grow 500pc; Immuron runs out of Travelan as travel rebounds
Health & Biotech
The Ethical Investor: Why Starpharma and these ASX biotechs could stop the next infectious disease outbreak
News
CLOSING BELL: ASX closed 0.11% lower, because there was no one around last night to tell us what to do
Health & Biotech
ASX biotechs are looking up, and the FDA breakthroughs are starting to flow
Health & Biotech
